News

Tenax Therapeutics has raised about $100 million in private funding to help accelerate the clinical development of oral levosimendan (TNX-103), a potential therapy for pulmonary hypertension(PH) due to heart failure with preserved ejection fraction (PH-HFpEF). The funding will help complete the ongoing placebo-controlled Phase 3 LEVEL…

People with pulmonary hypertension (PH) see worse outcomes following surgery to correct a hip fracture, a study shows. Among hip fracture patients, PH was associated with higher rates of post-surgical mortality, major in-hospital complications, and hospital re-admissions within three months. Those with severe PH had the worst outcomes after…

For people with pulmonary arterial hypertension (PAH) both with and without a few co-occurring heart problems, combination therapy with macitentan and tadalafil is similarly effective, according to a new analysis by researchers in the U.S. and Europe. “Initial combination therapy with macitentan plus tadalafil is efficacious in patients with…

Children of cigarette-smoking parents are at greater risk of developing pulmonary arterial hypertension (PHA) within a year after birth, according to a new study by researchers in Iran. Specifically, almost half of babies exposed to parental cigarette smoke were diagnosed with PAH, while none of the children with nonsmoking…

How chronic thromboembolic pulmonary hypertension (CTEPH) is managed across regions globally varies widely despite treatment advances, a survey study found, highlighting the need for more research, better guidelines, and ongoing education for healthcare providers. The study, “Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A…

The U.S. Food and Drug Administration has given Tectonic Therapeutic the go-ahead to start a Phase 2 clinical trial of TX45, the company’s experimental treatment for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). “We remain enthusiastic about the potential of TX45 to address the…

The U.S. Food and Drug Administration (FDA) has given orphan drug designation to ZM001, a first-in-class investigational antibody from Zymedi for pulmonary arterial hypertension (PAH). ZM001 is intended to reduce inflammation and tissue fibrosis (or scarring) in people with PAH. A Phase 1 clinical trial (NCT05967299) began dosing…

Patients with an intermediate to high risk of mortality in the first year following a pulmonary arterial hypertension (PAH) diagnosis have poorer health-related quality of life than those at lower risk, according to a study in England. Those costs were reduced following diagnosis, mainly due to less spending…

A committee of the European Medicines Agency (EMA) has recommended that Yuvanci, a tablet containing macitentan and tadalafil, be approved for pulmonary arterial hypertension (PAH). The positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) specifically recommends Yuvanci be approved for PAH in individuals with…

Measuring blood vessel function in the arm in a noninvasive way can help predict pulmonary hypertension (PH) when combined with certain heart measurements, a study has found. The study, “Endothelial Function Correlates With Pulmonary Pressures in Subjects With Clinically Suspected Pulmonary Hypertension,” was published in The American Journal…

Two molecules, 5-hydroxyindoleacetic acid (5-HIAA) and insulin-like growth factor 1 (IGF-1), showed a potential to diagnose pulmonary hypertension  early in children with congenital heart disease based on their levels in blood and urine samples examined in a study. 5-HIAA is the main product of the breakdown of serotonin, a…

Healthcare costs were found to be more than eight times higher for people with pulmonary arterial hypertension (PAH) compared with patients without the disease in a real-world study — which contributed to the greater economic burden seen for those being treated for PAH. These costs were mainly driven by…